Sophia Genetics SA

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SOPHiA GENETICS excels in Q4 2022, eyes biopharma growth

SOPHiA GENETICS reported strong financial performance in Q4 2022 and full-year 2022, driven by revenue growth, strategic partnerships, and operational efficiency improvements.
The company's focus on oncology and rare diseases, along with its multimodal approach and commitment to customer satisfaction, positions it well for sustained growth and value creation.
While facing challenges in maintaining growth momentum and managing operational metrics, SOPHiA has significant opportunities for expansion, partnerships, and leveraging AI for platform enhancement.

Sophia Genetics reports strong Q1 performance and eyes pharma growth

Sophia Genetics delivered strong Q1 results with revenue growth and customer expansions.
The company's focus on innovation and strategic partnerships positions it well for future growth.
While facing macro challenges and seasonal variability, Sophia Genetics remains optimistic about revenue growth.
Pharma partnerships and global presence offer significant growth opportunities for the company.

Sophia Genetics reports robust Q2 growth and strategic partnerships

Sophia Genetics delivered strong Q2 results with revenue growth and improved operating loss, driven by customer expansion and high growth areas like HRD testing and liquid biopsy.
While facing financial challenges, the company is actively managing costs and pursuing opportunities in innovative initiatives like DEEP-Lung-IV and MRD testing applications.
With a focus on sustaining growth and profitability, Sophia Genetics aims to leverage its strengths in genomics analytics and strategic partnerships to capitalize on market opportunities.
Investor confidence is reinforced by the company's reiterated annual guidance and expectations of continued growth, positioning Sophia Genetics for future success.

Sophia Genetics reports strong Q3 growth and strategic partnerships

Sophia Genetics delivered robust Q3 results, showing growth in revenue, customer adoption, and strategic partnerships.
Despite challenges in operating losses and lack of 2024 guidance, the company remains focused on sustainable growth and profitability.
Opportunities in precision medicine applications, FDA oversight alignment, and strong sales metrics position Sophia Genetics for continued success.

SOPHiA GENETICS reports strong Q4 earnings, eyes global expansion

SOPHiA GENETICS showcased robust financial performance, operational efficiency, and strategic growth initiatives in Q4 2023.
The company's focus on innovation, global expansion, and customer acquisition positions it well for future growth and market leadership.
Challenges in financial management and technology adaptation require careful navigation for sustained profitability and market competitiveness.
Opportunities in product expansion, market penetration, and strategic partnerships offer avenues for continued revenue growth and market expansion.

SOPHiA GENETICS reports solid Q1 performance and strategic growth plans

SOPHiA GENETICS reported solid Q1 performance with revenue growth to $15.8 million, strong bookings, and new logos signed.
Despite challenges in setup times and biopharma delays impacting revenue slightly, the company maintains full-year revenue guidance and operational targets.
Opportunities lie in emerging sequencing platforms adoption, new clinical business bookings, and potential acquisitions for growth and market leadership.
Overall, SOPHiA's strategic actions, competitive strengths, and commitment to sustainable growth position the company for continued success and expansion.

SOPHiA Genetics addresses revenue challenges, eyes growth opportunities in genomics

SOPHiA Genetics navigated challenges in Q2 with a focus on strategic actions and new opportunities. Despite revenue setbacks, the company is optimistic about future growth drivers and market initiatives. The revised full-year revenue outlook reflects a commitment to cost management and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOPHiA GENETICS technology to aid research associated with hereditary cancers and disorders  BOSTON and LAUSANNE, Switzerland , June 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey, is live on the SOPHiA DDM™ Platform. The hospital, which opened its doors in September 2022 and serves roughly 15,000 patients daily, will utilize multiple SOPHiA GENETICS solutions to streamline genomic testing, specifically associated with hereditary disorders.

Ankara Etlik City Hospital is Live on SOPHiA GENETICS Platform

SOPHiA GENETICS technology aids NOMAD Genetics in the advancement of its cancer research capabilities BOSTON and LAUSANNE, Switzerland , June 15, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic alliance with NOMAD Genetics. Headquartered in Mexico City and Chile, NOMAD is an innovative laboratory renowned for its specialization in genomics and clinical research.

NOMAD Genetics is Live on the SOPHiA GENETICS Platform

As a leader in data-driven medicine , SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot BOSTON and LAUSANNE, Switzerland , June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX, a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research.

SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research

Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland , May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023.

SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers BOSTON and LAUSANNE, Switzerland , May 24, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Institute of Oncology Ljubljana (IOL), a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™. To help advance its clinical oncology research, IOL is leveraging low-pass Whole Genome Sequencing (WGS) data computed by the proprietary GIInger deep-learning algorithm from SOPHiA GENETICS to increase research efficiency and obtain actionable clinical insights to make data-driven decisions that improve the quality of patient care.

Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research

SOPHiA GENETICS technology will help increase cancer research abilities BOSTON and LAUSANNE, Switzerland , May 16, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Natural State Laboratories, a xfull-service, state-of-the-art molecular laboratory based in Little Rock, Arkansas, has chosen SOPHiA GENETICS technology to help them expand their cancer testing and research capabilities. Natural State Laboratories will soon begin using SOPHiA DDM™ to launch in-house testing for hereditary cancers.

Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing

In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed BOSTON and LAUSANNE, Switzerland , May 8, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 samples analyzed for HRD status. This milestone comes just one year after implementing the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution.

Dasa Expands Its Capabilities with SOPHiA GENETICS

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

SOPHiA GENETICS SA (SOPH) Q1 2023 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.40 per share a year ago.

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

BOSTON and LAUSANNE, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) --  SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue for the first quarter of 2023 was $14.0 million, representing year-over-year growth of 29% on a reported basis over the corresponding period of 2022; Constant currency year-over-year revenue growth excluding COVID-19-related revenues was 37%.

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS' technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of ca.

SOPHiA GENETICS' SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award recognizes SOPHiA GENETICS' contributions in leading the way to democratizing data-driven medicine. Founded in Lausanne, Switzerland, SOPHiA GENETICS has been working to democratize data-driven medicine for over a de.

SOPHiA GENETICS Celebrates Swiss Biotech Award

BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST.

SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their capabilities around rare disease detection and treatment.

The University of Maryland Medical Center Chooses SOPHiA GENETICS Technology

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Krsnaa Diagnostics, India's largest diagnostic services provider in radiology and pathology, is live on SOPHiA DDM™ technology. Krsnaa Diagnostics is using the SOPHiA DDM™ for Hereditary Cancers Solution to expand their current next-generation sequencing (NGS) offerings.

Krsnaa Diagnostics is Live on SOPHiA GENETICS

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities.

Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics' track record of approved lab-developed tests that support clinical trials, cancer research and treatment.

Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test

SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?

Is it a good or bad thing when a stock experiences a golden cross technical event?

SOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis. Through the partnership, the SOPHiA DDMTM Platform will be integrated with Agilent's new Research Use Only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit.

SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2022 Results Earnings Conference Call March 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President, Investor Relations Jurgi Camblong - Founder and Chief Executive Officer Ross Muken - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Richard Hilliker, Jr. - Credit Suisse Mark Massaro - BTIG Marta Nazarovets - J.P. Morgan Operator Good morning and welcome to SOPHiA GENETICS' Fourth Quarter Fiscal 2022 Earnings Call.

SOPHiA GENETICS SA (SOPH) Q4 2022 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 35.29% and 3.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)---- $SOPH #Earnings--SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022. Recent Highlights Revenue for the full-year 2022 was $47.6 million, representing year-over-year growth of 18% on a reported basis. 2022 constant currency revenue growth excluding COVID-19-related revenues was 39% Revenue was $13.

SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS' platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies.

University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers

QIAGEN

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.

News for Sophia Genetics SA Stock (SOPH)